Biovica strengthens its commercial leadership

 Uppsala, Sweden, March 25, 2020. Biovica, active in cancer diagnostics, today announced that Robert Dann is joining the organization as SVP Marketing and US Business and will be part of the management team. The appointment marks a significant milestone in the upcoming commercialization of DiviTum[®] on the US market. 

2020-03-30T16:10:11+00:00 March 25th, 2020 08:30|Regulatory|

Positive results from Swedish study with DiviTum in metastatic breast cancer published in prestigious journal

Uppsala, Sweden, March 12, 2020. Biovica, active in cancer diagnostics, today announced that results from a study by researchers at Lund University have been published in the well renowned journal Scientific Reports, a journal from Nature. The results support that the blood test DiviTum can be used as a prognostic tool for evaluating treatment outcomes in metastatic breast cancer.

2020-03-30T16:10:11+00:00 March 12th, 2020 08:30|News|

Biovica provides updates on FDA application

Uppsala, Sweden, March 10, 2020. Biovica, active in cancer diagnostics, today announced that the company intends to submit an FDA application for market approval of DiviTum in the third quarter of 2020 and not as previously announced in mid-2020.

2020-03-30T16:10:11+00:00 March 10th, 2020 22:03|Regulatory|

Biovica strengthens management team

Biovica, active in cancer diagnostics, today announced that Henrik Winther was appointed SVP Business Development and will be part of the management team. He most recently comes from the role of SVP Precision Diagnostics at Immunovia.

2020-03-30T16:10:11+00:00 December 6th, 2019 08:00|News|

Biovica’s DiviTum – Strong prognostic marker in operable breast cancer

Uppsala, Sweden, November 20, 2019. Biovica, active in cancer biomarkers, today announced clinical data that demonstrate DiviTum as a strong prognostic marker in operable breast cancer. The results will be presented at the San Antonio Breast Cancer Symposium, SABCS, December 10-14, 2019, the world´s largest scientific congress focusing on breast cancer.

2020-03-30T16:10:12+00:00 November 20th, 2019 08:20|News|

Biovica’s DiviTum validated as a dynamic biomarker in metastatic breast cancer in collaboration with Institut Curie, Paris

Uppsala, Sweden, November 20, 2019. Biovica, active in cancer biomarkers, today announced that clinical data – demonstrating that DiviTum can be used as a dynamic, non-invasive biomarker for metastatic breast cancer patients treated with endocrine therapy and palbociclib – will be presented at the San Antonio Breast Cancer Symposium, December 10-14, 2019, the world´s largest scientific congress focusing on breast cancer.

2020-03-30T16:10:12+00:00 November 20th, 2019 08:00|News|

Biovica strengthens with new R&D Director

Uppsala, November 15, 2019. Biovica, active in cancer diagnostics, today announced that Otti Bengtsson Gref has been appointed new R&D Director and will be part of the management team. She most recently comes from the role as R&D Director at Cavidi.

2020-03-30T16:10:12+00:00 November 15th, 2019 08:00|Regulatory|